학술논문
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
Document Type
article
Author
Matthias Gromeier; Michael C. Brown; Gao Zhang; Xiang Lin; Yeqing Chen; Zhi Wei; Nike Beaubier; Hai Yan; Yiping He; Annick Desjardins; James E. Herndon; Frederick S. Varn; Roel G. Verhaak; Junfei Zhao; Dani P. Bolognesi; Allan H. Friedman; Henry S. Friedman; Frances McSherry; Andrea M. Muscat; Eric S. Lipp; Smita K. Nair; Mustafa Khasraw; Katherine B. Peters; Dina Randazzo; John H. Sampson; Roger E. McLendon; Darell D. Bigner; David M. Ashley
Source
Nature Communications, Vol 12, Iss 1, Pp 1-7 (2021)
Subject
Language
English
ISSN
2041-1723
Abstract
Recurrent glioblastomas (rGBM) have dismal outcomes, but long-term survival has been observed in subsets of patients after immunotherapy. Here the authors report a positive association between low tumor mutation burden, inflammatory gene signatures, and survival after immunotherapy in rGBM patients.